Back to Search
Start Over
Ipsen expands license agreement with Exelixis for development of Cabometyx in advanced neuroendocrine tumours
- Source :
- PharmaBiz. July 4, 2024
- Publication Year :
- 2024
-
Abstract
- Ipsen, a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: oncology, rare disease and neuroscience, has announced confirmation of an expanded collaboration [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.800059484